For some men considering focal therapy, one of the biggest questions is what happens later.
If prostate cancer is found again, does that mean surgery? Does the whole prostate have to be removed? Did choosing focal therapy the first time limit your future options?
The answer is: it depends. In many eligible cases, prostate cancer can be treated again without immediately removing or treating the whole prostate.
One advantage of focal therapy is that treatment decisions can remain. If a clinically significant prostate cancer is found again after HIFU or NanoKnife (IRE – Irreversible Electroporation), the next step is not automatically removal or treatment of the whole prostate. In eligible cases, another focal treatment can still be considered.
Focal Therapy Treats the Cancer Target, Not Necessarily the Whole Prostate
With radical prostatectomy, the prostate is removed. With radiation, the whole gland is usually treated.
In focal treatment, the prostate remains in place. HIFU can be used focally or, in some cases, for whole-gland ablation. NanoKnife (IRE) is always focal (sometimes multi-focal), treating the cancer target while preserving the rest of the gland. The goal is to treat the clinically significant cancer while limiting damage to surrounding tissue, including structures involved in urinary control and sexual function.
That is why focal therapy planning is so detailed. We look at the MRI, biopsy results, PSA history, prostate anatomy, cancer location, and your priorities before deciding whether treatment can be targeted safely.
The treatment is not chosen simply because it is less invasive. It is chosen because the cancer appears suitable for a focused approach and we are confident in achieving a very high cure rate.
Thinking Beyond the First Treatment
When you are first diagnosed with prostate cancer, it is natural to focus on the immediate decision: treating the cancer while minimizing the risk of side effects.
Prostate Cancer Treatment Options
But prostate cancer treatment also requires long-term thinking. Some men worry that if they choose focal therapy and cancer is found again later, they will have no good options left.
In reality, the next step depends on the details: where the cancer is found, if it is recurrent or a new focal cancer, how aggressive it is, and whether another targeted treatment remains appropriate.
The Most Important Question
When cancer is found after focal therapy, the question is not simply, “Is it back?”
The more important question is: where is it?
Cancer found in the previously treated area is evaluated differently from cancer found elsewhere in the prostate.
A finding in the treated area can mean the original cancer extended beyond what imaging or biopsy showed before treatment, or that cancer has returned in that area after a period of control.
Cancer found elsewhere in the prostate can represent a separate area of disease that was not part of the original treatment target. That is not the same as the failure of the treated zone.
This distinction matters because it helps us determine the next step. A small, low-grade finding can sometimes be monitored. Clinically significant cancer requires a more active discussion.
When Repeat Focal Treatment Can Be Considered
Repeat focal treatment is considered when the cancer can still be clearly identified, mapped, and treated safely.
That decision depends on several factors:
- Where the cancer is located
- Whether it is in the treated area or another part of the prostate
- The Grade Group or Gleason score
- The amount of cancer found
- Whether the cancer is visible on MRI
- PSA pattern over time
- Prostate size and anatomy
- Previous treatment effects
- Your priorities around preserving urinary control and sexual function
- Your age and overall health
If the cancer is localized and the anatomy is favourable, another targeted treatment can be an option.
This is one of the reasons follow-up after focal therapy matters. PSA testing, MRI, and biopsy when needed do more than look for problems. They help define the next decision clearly.
Treatment Choice Depends on Location
HIFU and NanoKnife (IRE) are both focal therapy technologies, but they work differently.
HIFU uses focused ultrasound energy to heat and destroy targeted prostate tissue. NanoKnife (IRE) uses electrical pulses to disrupt cell membranes within the treatment zone, leading to cell death.
Because the technologies work differently, lesion location can influence which approach is preferred. A cancer near the apex, urethra, neurovascular bundles, rectum, or prostate capsule can raise different planning concerns than a cancer in another part of the gland. Previous treatment can also change the tissue and affect the safest approach.
This is one reason UIC offers both HIFU and NanoKnife (IRE). When a clinic offers only one focal therapy technology, treatment planning can be shaped by that limitation. At UIC, eligible patients are evaluated for both approaches, so recommendations are guided by clinical factors rather than treatment availability.
If cancer is detected in a previously treated area, we review the original treatment, the new biopsy findings, MRI visibility, and the location of the recurrence.
In some cases, another focal treatment can be considered using a different energy source. For example, if NanoKnife (IRE) was used first, HIFU may be an option depending on the anatomy and clinical findings.
This is why access to both technologies matters: retreatment planning is not limited to repeating the same approach.
Retreatment Is Not Automatic
The fact that repeat focal treatment can be considered does not mean it is always the right choice.
Some men are better served by surgery, radiation, active surveillance, or systemic treatment if the cancer is no longer localized. This depends on how aggressive the cancer is, where it is found, and whether the prostate can still be treated safely with a targeted approach.
Repeat focal therapy is not the goal. Choosing the right next treatment is.
That is why we do not make retreatment decisions from PSA alone. A rising PSA can signal that something needs attention, but it does not tell the whole story. MRI, biopsy, ultrasound, PSMA PET/CT in selected cases, and clinical judgment help clarify what is happening.
How This Differs From Whole-Gland Treatment
One reason men consider focal therapy is that, in suitable cases, the first step does not have to be removal or whole-gland treatment of the prostate.
After radical prostatectomy, the prostate has been removed. After radiation, the whole gland has already been treated, which can make additional local treatment more complex.
After focal therapy, the majority of the prostate remains in place. The treated area has been addressed, but the remaining “normal” tissue must be monitored and if changes are detected, and, in eligible cases, may be appropriate for future targeted treatment.
The Main Advantage: Another Decision Remains Possible
You may hear “prostate cancer treatment” and assume the choice is final: remove the prostate, radiate the whole gland, and live with the consequences.
Focal therapy offers a different approach. It allows us to treat the known cancer while preserving the prostate and protecting future options. If prostate cancer is found again, we can review the new information, map the cancer, assess your PSA pattern and function, and help determine the most appropriate next step.
In some cases, that next step can be another focal treatment. In others, we may recommend monitoring, surgery, radiation, or systemic treatment if the cancer is no longer localized.
At Urology Innovations Canada, we do not assume the next step. We look at the cancer, the prostate, the prior treatment, and the man in front of us.
That is the real value of keeping options open.
If you have localized prostate cancer and want to understand whether HIFU or NanoKnife IRE could preserve future treatment options, send us a consultation request.